- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
January 15, 2021Robins Kaplan Partners Named to IAM Strategy 300 Global Leaders Guide
-
January 12, 20212025 Goals - Our commitment to Inclusion, Diversity, and Equity
-
January 5, 2021Litigator Mark Hallberg Joins Robins Kaplan LLP
-
January 28, 2021COVID-19: The Show Did Not Go On
-
February 9, 2021Smart Phone Privacy and Data Security – How to Assess and Minimize Risk in the Current Reality
-
March 6, 2021With Our Voices 2021 Arc Gala
-
2020Clear Evidence Clarified
-
December 27, 2020Covid-19 Relief Bill Provides Long-Awaited Funding to Small Businesses and Individuals
-
December 17. 2020Covid-19 Divorce and Marital Property Agreements
-
January 15, 2021Financial Daily Dose 1.15.2021 | Top Story: As Unemployment Claims Surge, Biden Unveils $1.9T Covid Recovery Proposal
-
January 14, 2021Financial Daily Dose 1.14.2021 | Top Story: Intel Ousts CEO Robert Swan After Just Two Years
-
January 13, 2021Financial Daily Dose 1.13.2021 | Top Story: Visa Jettisons Plaid Takeover After DOJ Antitrust Challenge
Antitrust Plays Whack-a-Mole as Exclusion of Competition by Drug Monopolists Pops Up Again: Gaming the “REMS”
Some brand-name drug manufacturers have used various tactics—some lawful and some arguably unlawful—in an effort to delay generic competition and maintain monopoly profits.
Fall 2016
The pharmaceutical industry is a big business. Top selling drugs, many protected by patents, often sell at prices reflecting the monopoly power that brand-name drug manufacturers may enjoy. Enter the fray, generic competition, offering patients therapeutic equivalents to brand-name drugs at a fraction of the cost--saving consumers hundreds of billions of dollars each year. The first generic drug to come to market is typically offered at a price discount of 20% to 30% off the brand-name, with entry by additional generic competitors driving the discount to as much as 90%.
Reprinted with permission from: NYLitigator, Fall 2016, Vol. 21, No. 2, published by the New York State Bar Association, One Elk Street, Albany, New York, 12207
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.